{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-22-000051","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.162035+00:00","generated_at":"2026-06-26T19:30:10.264819+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Emergent appoints Harsanyi chairman, Katkin to board; El-Hibri retires as executive chairman","bullets":["Zsolt Harsanyi, Ph.D., independent director since 2004, appointed non-executive chairman effective April 1, 2022.","Keith Katkin appointed Class I independent director, receives initial equity award of $375,000 in RSUs vesting over 3 years.","Founder Fuad El-Hibri retires as executive chairman; enters consulting agreement at $20,000/month (up to 20 hours) through March 2024.","Board eliminates executive chairman role; Marvin White, Jerome Hauer, Kathryn Zoon appointed chairs of audit, strategic operations, and scientific review committees.","El-Hibri's unvested equity awards continue to vest during consulting term; subject to non-compete and non-solicitation through 12 months post-termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-22-000051","json":"https://secwatch.observer/filing/0001367644-22-000051.json","markdown":"https://secwatch.observer/filing/0001367644-22-000051.md","text":"https://secwatch.observer/filing/0001367644-22-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/ebs-20220317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T19:30:10.264819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12d7cc5b25","claim":"Fuad El-Hibri resigned as Executive Chairman at Emergent BioSolutions Inc..","evidence_excerpt":"Fuad El-Hibri, Founder and Executive Chairman of the Board, notified the Company of his retirement and resignation as an officer, director and employee of the Company, effective as of April 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"7d0f085507","claim":"Keith Katkin was appointed as Class I director at Emergent BioSolutions Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764422000051/0001367644-22-000051-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}